Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
- PMID: 10794683
- DOI: 10.1021/jm9909645
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
Abstract
A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described. The compounds were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC(50)) of 55 pM for the cloned human GLP-1 receptor. Many of the compounds had similar or even higher potencies, despite quite large substituents. All compounds derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients. A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency. Derivatization with two fatty acid substituents led to a considerable loss of potency. A structure-activity relationship on derivatization of specific amino acids generally was obtained. It was found that the longer the fatty acid, the more potency was lost. Simultaneous modification of the N-terminus (in order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.
Similar articles
-
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.Biol Chem. 2004 Feb;385(2):169-77. doi: 10.1515/BC.2004.035. Biol Chem. 2004. PMID: 15101559
-
Therapeutic strategies based on glucagon-like peptide 1.Diabetes. 2004 Sep;53(9):2181-9. doi: 10.2337/diabetes.53.9.2181. Diabetes. 2004. PMID: 15331525 Review.
-
Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.Biochemistry. 2001 Mar 6;40(9):2860-9. doi: 10.1021/bi0014498. Biochemistry. 2001. PMID: 11258897
-
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981. Am J Physiol. 1997. PMID: 9374685 Clinical Trial.
-
The potential role of glucagon-like peptide 1 in diabetes.Curr Opin Investig Drugs. 2004 Apr;5(4):402-10. Curr Opin Investig Drugs. 2004. PMID: 15134281 Review.
Cited by
-
The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity.Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2415550121. doi: 10.1073/pnas.2415550121. Epub 2024 Sep 19. Proc Natl Acad Sci U S A. 2024. PMID: 39297680 Free PMC article.
-
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.Front Endocrinol (Lausanne). 2024 Jul 24;15:1431292. doi: 10.3389/fendo.2024.1431292. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39114288 Free PMC article. Review.
-
Redefining peptide therapeutics with semaglutide.Nat Chem. 2024 Feb;16(2):296. doi: 10.1038/s41557-023-01434-4. Nat Chem. 2024. PMID: 38321235 No abstract available.
-
Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.Acta Pharmacol Sin. 2012 Mar;33(3):300-11. doi: 10.1038/aps.2011.170. Epub 2012 Jan 23. Acta Pharmacol Sin. 2012. PMID: 22266723 Free PMC article. Review.
-
Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article.Cureus. 2021 May 20;13(5):e15141. doi: 10.7759/cureus.15141. Cureus. 2021. PMID: 34164242 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases